ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2013 - 2026)

As of Dec 31, 2025, ProQR Therapeutics reported Total Non-Current Liabilities of $34.96 million, down 20.2% from the prior year.

• Annual Total Non-Current Liabilities has declined for three straight years, with a five-year compound annual growth rate of -0.8% (years ended Dec 2020 to Dec 2025).
• Across earlier years, Total Non-Current Liabilities came in at $43.83 million in the year ended Dec 31, 2024 (-35.0%), $67.38 million in the year ended Dec 31, 2023 (-23.6%), $88.17 million in the year ended Dec 31, 2022 (+8.4%) and $81.36 million in the year ended Dec 31, 2021 (+123.5%).
• The figure for the quarter ended Jun 30, 2026 is the lowest quarterly Total Non-Current Liabilities since the quarter ended Dec 31, 2019.
• On a year-over-year basis, Total Non-Current Liabilities has declined for 11 consecutive quarters, with an average decline of 38.1% over the last eight quarters.
• Peak year-over-year performance for Total Non-Current Liabilities in the last five years was growth of 106.9% in the quarter ended Dec 31, 2021, against a decline of 57.4% in the quarter ended Mar 31, 2025 at the low end.
• Per Business Quant, the preceding three quarters came in at $30.88 million (quarter ended Mar 31, 2026), $36.02 million (quarter ended Dec 31, 2025) and $39.91 million (quarter ended Sep 30, 2025).